Zai Lab and Baozun add to HK ECM momentum

Hong Kong_adobe_12May_575
By Rashmi Kumar
17 Sep 2020

US-listed Chinese companies Zai Lab and Baozun have kicked off secondary offerings on the Hong Kong Stock Exchange, adding further momentum to the city’s already hot equity capital market.

Zai Lab, a biopharmaceutical company that focuses on oncology, as well as infectious and autoimmune diseases, is working with Citi, Goldman Sachs and JP Morgan as the listing sponsors.

There are about 10.56m shares in the base offer, plus an additional 1.58m shares for over-allotment. Bookbuilding will ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial